Table 3.

Multivariate analyses of biomarkers for PFS and OS in 48 bmCRPC-patients on Enzalutamide-therapy without PSA-response

Progression Free Survival			Overall Survival
Variable	HR (95% CI)	P	Variable	HR (95% CI)	P
ALP rising at 12 weeks Yes No	1 (reference) 0.77 (0.22–2.69)	0.68	ALP rising at 12 weeks Yes No	1 (reference) 1.14 (0.32–4.09)	0.83
ALP rising at 12 weeks, without LDH normalization Yes No	1 (reference) 0.70 (0.18–2.67)	0.6	ALP rising at 12 weeks, without LDH normalization Yes No	1 (reference) 0.31 (0.08–1.13)	0.08
Enzalutamide after chemotherapy Yes No	1 (reference) 0.55 (0.28–1.09)	0.09	Enzalutamide after chemotherapy Yes No	1 (reference) 0.36 (0.17–0.78)	0.01
ECOG > 0 Yes No	1 (reference) 0.78 (0.41–1.49)	0.44	ECOG > 0 Yes No	1 (reference) 0.77 (0.39–1.52)	0.45
Visceral metastases Yes No	1 (reference) 0.92 (0.44–1.92)	0.82	Visceral metastases Yes No	1 (reference) 0.95 (0.44–2.05)	0.89
Abbreviations: PFS: progression-free survival; OS: overall survival; HR: hazard ratio; 95% CI: 95% confidence interval; ALP: alkaline phosphatase; LDH: lactate dehydrogenase; bmCRPC: bone metastatic castration-resistant prostate cancer; PSA: prostate specific antigen; ECOG: eastern cooperative oncology group performance status